| Literature DB >> 24565416 |
Jun Nagano1, Takako Morita, Koji Taneichi, Shohei Nagaoka, Sadanobu Katsube, Tomiaki Asai, Masao Yukioka, Kiyoshi Takasugi, Masakazu Kondo, Yasuro Nishibayashi.
Abstract
BACKGROUND: The repression of negative emotions is a personality factor that received considerable attention in the 1950-60s as being relevant to the onset and course of rheumatoid arthritis (RA). Despite subsequent, repeated criticisms of the cross-sectional nature of the earlier studies, even to date few prospective studies have been reported on this issue. This multicenter study prospectively examined if "rational and antiemotional" behavior (antiemotionality), characterized by an extreme tendency to suppress emotional behaviors and to rationalize negative experiences in conflicting interpersonal situations, is associated with the functional prognosis of patients with RA.Entities:
Year: 2014 PMID: 24565416 PMCID: PMC3941968 DOI: 10.1186/1751-0759-8-8
Source DB: PubMed Journal: Biopsychosoc Med ISSN: 1751-0759
Demographic and baseline clinical characteristics of patients with rheumatoid arthritis (N = 460)
| Age, yrs, mean (SD) | 56.1 | (9.6) |
| Female | 406 | (88.3) |
| Education completed | | |
| Junior high school | 114 | (24.8) |
| High school | 251 | (54.6) |
| Junior college or higher | 95 | (20.6) |
| Disease duration, yrs, mean (SD) | 11.4 | (9.5) |
| ACR class | | |
| 1 | 76 | (16.5) |
| 2 | 322 | (70.0) |
| 3 | 62 | (13.5) |
| Joint stage* | | |
| 1 | 55 | (12.0) |
| 2 | 98 | (21.3) |
| 3 | 113 | (24.6) |
| 4 | 194 | (42.2) |
| Afflicted joint* count (0–49), mean (SD) | 10.0 | (8.8) |
| No. of extra-articular complications* | | |
| 0 | 351 | (76.3) |
| 1 | 83 | (18.0) |
| 2+ | 26 | (5.7) |
| C-reactive protein, mg/dl, mean (SD) | 1.63 | (2.11) |
| Medical treatments† | | |
| Methotrexate use | 194 | (42.2) |
| Corticosteroids use | 205 | (44.6) |
| Other DMARDs use | 246 | (53.5) |
SD: standard deviation, ACR: American College of Rheumatology, DMARDs: disease modifying anti-rheumatic drugs. *See text for explanation. †Based on a yes/no choice. Values are N (%) unless otherwise stated.
Association at baseline between antiemotionality and the demographic and clinical characteristics of patients with rheumatoid arthritis (N = 460)
| Female | 82.8 | 86.6 | 95.0 | .001 |
| Age, yrs, mean (SD) | 54.9 (10.0) | 56.0 (10.3) | 57.4 (8.5) | .033 |
| Education, college or higher | 22.8 | 20.4 | 19.0 | .85 |
| Duration, yrs, mean (SD) | 11.6 (9.8) | 9.9 (8.5) | 12.7 (10.0) | .41 |
| ACR class > = 3 | 13.8 | 11.5 | 15.2 | .75 |
| Joint stage‡ > = 3 | 65.5 | 66.2 | 68.4 | .45 |
| Afflicted joints‡ count, mean (SD) | 9.9 (9.4) | 9.0 (7.8) | 11.1 (9.0) | .028 |
| No. extra-articular complications‡ > = 1 | 23.5 | 23.0 | 24.7 | .49 |
| CRP, mg/dl, mean (SD) | 1.49 (1.87) | 1.76 (2.50) | 1.63 (1.90) | .12 |
| Methotrexate use | 38.6 | 43.4 | 44.3 | .48 |
| Corticosteroids use | 44.8 | 42.0 | 46.8 | .86 |
| Other DMARDs use | 54.5 | 54.1 | 51.9 | .95 |
RCF: rationalizing conflicts/frustrations. ACR: American College of Rheumatology, CRP: C-reactive protein, DMARDs: disease modifying anti-rheumatic drugs. *The score of the rationalizing conflicts/frustrations scale of the Stress Inventory; the degrees of antiemotionality, “low”, “moderate”, and “high”, were based on the tertiles of the RCF score, 3.8 and 4.6. †Based on Spearman’s rank correlation. ‡See text for explanation. Values are % unless otherwise stated.
Figure 1Changes in the functional status of patients with rheumatoid arthritis according to the degree of antiemotionality. RCF score: the score of the rationalizing conflicts/frustrations scale of the Stress Inventory; “low”, “moderate” and “high” represent the RCF score of < 3.8, 3.8 to < 4.6, and 4.6+, respectively. ACR: American College of Rheumatology. BL: at the time of the baseline survey, 2Y: two years after the baseline survey.
Multiple logistic regression analysis of the association between antiemotionality at baseline and the functional prognosis (ACR class at follow-up) of patients with rheumatoid arthritis
| Antiemotionality (RCF score*) | 1.40 | (1.05-1.87) | .023 | 1.47 | (1.07-2.00) | .016 |
| ACR class | 10.52 | (5.87-18.9) | <.001 | 6.13 | (3.17-11.8) | <.001 |
| Female sex | | | | 1.92 | (0.53-6.98) | .32 |
| Age | | | | 1.00 | (0.96-1.04) | .99 |
| Joint stage* | | | | 1.20 | (0.80-1.78) | .38 |
| Afflicted joints* count | | | | 1.03 | (1.00-1.07) | .06 |
| No. extra-articular complications* | | | | 1.40 | (0.96-2.02) | .08 |
| Log. C-reactive protein | | | | 1.30 | (0.99-1.71) | .06 |
| Methotrexate use | | | | 1.39 | (0.67-2.88) | .38 |
| Corticosteroids use | | | | 0.43 | (0.20-0.94) | .034 |
| Other DMARDs use | | | | 1.12 | (0.54-2.32) | .76 |
| Education level | 0.80 | (0.52-1.23) | .30 | |||
ACR: American College of Rheumatology. OR: odds ratio of a poorer function (Class 3 or 4) vs. a better function (Class 1 or 2) at follow-up. CI: confidence interval. RCF: rationalizing conflicts/frustrations. *See text for explanation.